HBV
Conditions
Interventions
Case series:nucleoside (acid) analogues after 24 weeks of sequential or combined treatment with pegylated interferon alfa-2b
Sponsors
First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged 18-45 years; 2. Patients with chronic hepatitis B received nucleoside (acid) analogues for at least one year, and HBV DNA was below the detection limit; 3. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients during pregnancy or lactation; 2. Compensation or decompensation of hepatitis B cirrhosis; 3. Patients with viral hepatitis A, C, D, E and HIV infection; 4. Autoimmune liver disease, metabolic liver disease, alcoholic liver disease, malignant tumors, decompensated liver disease and organ transplantation patients; 5. Patients with severe neurological or psychiatric disorders; 6. Patients with severe hyperthyroidism and other autoimmune diseases; 7. Diabetic patients with poor blood sugar control; 8. Patients with retinal or fundus lesions; 9. Non-abstinent alcoholics/drug addicts; 10. Patients with severe heart disease, coronary heart disease and cerebrovascular disease; 11. Patients with poor epilepsy control; 12. Patients with contraindications in IFN instructions or Chinese guidelines for the treatment of chronic hepatitis C; 13. Researchers evaluated patients who were not suitable for admission.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBsAg; | — |
Contacts
Public ContactLu Xiaobo
First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed